Compounded GLP-1 After FDA Shortage Removal: What Changes

You have been waiting for compounded GLP-1 to become available and affordable. Or you are already on a compounded program and wondering whether it will still be accessible in 2026. Now you are hearing about the FDA removing these medications from the drug shortage list. What does that actually mean for you?

The short answer: the regulatory landscape is actively changing, and availability is becoming less certain. This guide explains what happened, why it matters, and what you should be thinking about now.

Why compounded GLP-1 existed in the first place

Compounded GLP-1 medications exist because of a specific federal law. Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act^[1] allow licensed compounding pharmacies to prepare copies of drugs that appear on the FDA’s official drug shortage list^[2].

When semaglutide and tirzepatide were added to that shortage list, it was because demand for these medications dramatically exceeded supply^[3]. Patients who wanted access to GLP-1 medications faced months-long waitlists at branded manufacturers. Compounding pharmacies stepped in legally to fill that gap. They prepared compounded versions at a fraction of the branded cost.

That shortage designation was the foundation for the entire compounded GLP-1 market. Without it, pharmacies would not have had a legal basis to compound these drugs at scale.

What the FDA did in 2025: Shortage resolution and enforcement

In early 2025, the FDA announced that the shortage of tirzepatide had been resolved^[4]. Supply had caught up with demand. Pharmaceutical manufacturers had ramped production capacity. The medical need that justified emergency compounding was no longer acute.

What happened next was significant. The FDA issued official guidance indicating that 503B outsourcing facilities could no longer legally compound tirzepatide for non-patient-specific uses once the shortage was resolved^[5]. These large-batch compounders were operating under the emergency authority of the shortage designation. That authority expired.

The FDA followed this guidance with enforcement action^[6]. Warning letters were issued to compounding pharmacies and online telehealth companies continuing to produce and market compounded tirzepatide after the shortage resolution. The FDA’s position was clear: the legal basis for compounding tirzepatide had ended.

The same reasoning was then applied to semaglutide as supply stabilized in late 2025. The FDA proposed to treat semaglutide the same way. As supply improves and the shortage designation moves closer to removal, 503B facilities face similar enforcement pressure.

Understanding 503A vs 503B: Why the distinction matters

This is where things get complicated. Compounding pharmacies operate under two different regulatory frameworks, and they face different legal pressures as shortages are resolved.

503B outsourcing facilities are FDA-registered, large-batch compounders^[7]. They can prepare medications without a patient-specific prescription on file. They produce bulk inventory that can be distributed to healthcare providers and telehealth platforms. When the FDA ended the shortage designation, it used that as justification to restrict what 503B facilities can legally compound. The FDA’s enforcement has focused here first.

503A pharmacies are state-licensed, traditional compounders^[8]. They prepare medications for specific patients based on individual prescriptions. They operate under state pharmacy board oversight, not primary FDA registration (though the FDA has some authority). After a shortage is resolved, the legal situation for 503A pharmacies is more complex. Some state pharmacy boards and legal experts argue that patient-specific compounding continues to be permitted under different legal authority, separate from the shortage list. This disagreement between states, the FDA, and pharmacy advocates has created legal uncertainty.

The practical effect is this: 503B facilities that produced bulk compounded GLP-1 are facing stricter enforcement and many have ceased production. 503A facilities continue to operate in many states, but availability is inconsistent and decreasing. The landscape is fragmenting.

Current status as of early 2026: Honest about uncertainty

The regulatory situation remains actively evolving. Court challenges from compounding pharmacies and patient advocacy groups have slowed FDA enforcement in some cases. Some pharmacies continue to operate; others have shut down compounded GLP-1 production entirely.

FDA Shortage Resolution Timeline

The FDA has removed both semaglutide and tirzepatide from its official drug shortage list:

Tirzepatide: The FDA declared the tirzepatide shortage resolved on December 19, 2024. The enforcement discretion period for 503A state-licensed pharmacies ended on February 18, 2025. The enforcement discretion period for 503B outsourcing facilities ended on March 19, 2025. After these dates, the FDA has actively discouraged continued compounding of tirzepatide.

Semaglutide: The FDA removed semaglutide from the drug shortage list on February 21, 2025. The enforcement discretion period for 503A pharmacies ended on April 22, 2025. The enforcement discretion period for 503B facilities ended on May 22, 2025.

What this means: Once a drug is removed from the shortage list, the primary legal justification for compounding pharmacies to prepare that drug at scale disappears. 503B outsourcing facilities (which prepare bulk inventory) face the most immediate pressure and enforcement risk. 503A pharmacies (which compound patient-specific prescriptions) operate under a more complex legal framework, and their status continues to evolve.

Current Availability (April 2026)

Here is what we know:

• The FDA shortage designation for tirzepatide has been removed (as of early 2025).
• The FDA shortage designation for semaglutide has been removed (as of February 2025).
• 503B facilities (large-batch compounders) have largely ceased GLP-1 production due to FDA enforcement pressure.
• 503A facilities (patient-specific compounders) remain in operation in most states but with reduced inventory and increasing state-by-state variation.
• Availability of compounded GLP-1 varies significantly by region and provider.
• As of April 2026, compounded programs remain available through some providers but cannot be guaranteed indefinitely.

Patients on compounded programs should expect that this may not remain an option permanently. The legal environment continues to shift. The availability you have today may not be available in six months.

What happens when compounded access ends

If shortages are removed and FDA enforcement intensifies, compounded GLP-1 access will likely continue to decline. When that happens, patients who depend on compounded medications face a choice.

The first option is to evaluate branded GLP-1 medications through insurance. Some insurance plans now cover semaglutide or tirzepatide for weight loss (not just diabetes or heart disease). Employer plans and ACA marketplace plans increasingly include coverage. If your insurance covers the branded version, the out-of-pocket cost may be manageable or even lower than you would expect.

If insurance is not available, manufacturer patient assistance programs may help. Brand-name manufacturers offer programs for income-qualifying patients that substantially reduce or eliminate the cost of their medications. These programs have eligibility requirements based on income and insurance status, but many patients qualify.

For patients who cannot access branded medications through insurance or assistance, the reality is difficult. You may need to focus on maintaining your weight loss through intensive lifestyle management. This is not ideal, but it is the medical reality if medication access becomes unavailable. Many providers work with patients on lower-dose maintenance strategies or extended intervals between doses if any compounded access continues.

Some ongoing research trials are also enrolling patients with weight loss and obesity-related conditions. If you are interested in accessing GLP-1 medications through clinical trials, your provider can discuss whether you qualify.

What Transformation Health’s approach is

Transformation Health partners exclusively with licensed, US-based compounding pharmacies. We do not work with offshore pharmacies, unapproved sources, or facilities with compliance issues.

On all compounded medication content, we include clear disclosures that these medications are not FDA-approved, that availability is subject to FDA drug shortage-list status, and that programs may change. We do not market compounded medications as substitutes for branded drugs or imply that they are equivalent to FDA-approved products.

As the regulatory environment changes, our available programs will change. If a pharmacy we work with ceases production due to FDA enforcement, we transition patients to alternative options or work with providers to explore branded medications, patient assistance programs, or other legitimate pathways.

We believe in transparency about this uncertainty from the start. Patients should know they are choosing a program whose regulatory foundation is shifting. That is not a flaw we hide. It is information that helps you make an informed decision.

The longer view: What happens to GLP-1 access when the shortage era ends

The GLP-1 shortage era enabled unprecedented access to weight loss medications for middle-income patients without insurance. For a period, you could access semaglutide or tirzepatide for $249 to $399 per month through a telehealth provider. That was transformational.

As pharmaceutical manufacturers scaled up production and shortage designations are lifted, that era is ending. The compounded market is contracting. Brand-name GLP-1 pricing remains high. For patients with good insurance, branded GLP-1 is now broadly accessible. For patients without insurance, the access gap is widening again.

This is not about compounded medications being unsafe or ineffective. It is about the regulatory foundation shifting beneath an entire access pathway. Shortages were the legal mechanism that permitted compounding at scale. As shortages resolve, that mechanism disappears.

Policy discussions are ongoing. The Treat and Reduce Obesity Act proposes Medicare coverage for weight loss medications^[10]. Coverage expansion for Medicaid is being debated in some states. But as of April 2026, these policy changes have not yet happened. The access gap remains.

The takeaway: if you are currently on a compounded GLP-1 program, understand that this pathway may not be available in 12 months. Plan accordingly. Talk with your provider about alternatives. If insurance coverage is possible, explore it now. If patient assistance programs apply to you, gather that information. You are not being punished for choosing compounded medications; you are navigating a healthcare system that is in transition.

Citations

[1] 21 U.S.C. Section 503A and 503B - Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

[2] FDA. “Drug Shortages List.” https://www.accessdata.fda.gov/scripts/drugshortages/

[3] FDA. “Historical Drug Shortage Data.” https://www.accessdata.fda.gov/scripts/drugshortages/

[4] FDA. “Drug Alerts and Statements.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/drug-alerts-and-statements

[5] FDA. “Guidance on 503B Compounding After Shortage Resolution.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act

[6] FDA. “Warning Letters to Compounding Pharmacies (2025).” https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

[7] FDA. “Registered Outsourcing Facilities.” https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities

[8] FDA. “State-Licensed Compounding Pharmacies (503A).” https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act

[9] FDA. “Tirzepatide Shortage Resolution Status.” https://www.accessdata.fda.gov/scripts/drugshortages/

[10] U.S. Senate. “Treat and Reduce Obesity Act.” https://www.congress.gov/